Home > Insider Trading > Filing (0001214659-22-000857)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1576263	Mirati Therapeutics Inc.	MRTX	Pharmaceutical Preparations (2834)	462693615

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1599324	Jamie Christensen	C/O Mirati Therapeutics 3545 Cray Court San Diego CA 92121	Evp, Chief Scientific Officer	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2022-01-14	10,755	$0.00	88,055	No	4	A	Direct
Common Stock	Disposition	2022-01-18	627	$120.51	87,428	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	A	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (Right to Buy)	Acquisiton	2022-01-14	17,821	$0.00	17,821	$124.31

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
17,821		2032-01-13	No	4	A	Direct

Footnotes

Grant of Restricted Stock Units (RSUs). Shares will vest 25% annually on the anniversary of the grant date until fully vested.
Represents shares sold by the Company to satisfy the tax withholding obligation associated with the vesting of a portion of the restricted stock units (RSUs) granted on January 15, 2021.
The price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $120.49 to $121.145, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
25% of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of the shares subject to the Option shall vest each month thereafter until fully vested.